Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

In this phase 2 study, investigators evaluated the potential of two vaccines (H4:IC31 and BCG) to prevent the acquisition of tuberculosis infection and the subsequent development of sustained disease.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 379; no. 2; pp. 138 - 149
Main Authors Nemes, Elisa, Geldenhuys, Hennie, Rozot, Virginie, Rutkowski, Kathryn T, Ratangee, Frances, Bilek, Nicole, Mabwe, Simbarashe, Makhethe, Lebohang, Erasmus, Mzwandile, Toefy, Asma, Mulenga, Humphrey, Hanekom, Willem A, Self, Steven G, Bekker, Linda-Gail, Ryall, Robert, Gurunathan, Sanjay, DiazGranados, Carlos A, Andersen, Peter, Kromann, Ingrid, Evans, Thomas, Ellis, Ruth D, Landry, Bernard, Hokey, David A, Hopkins, Robert, Ginsberg, Ann M, Scriba, Thomas J, Hatherill, Mark
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 12.07.2018
Subjects
Adolescents
Antigens
Bacillus Calmette-Guerin vaccine
BCG
Clinical significance
Disease prevention
Disease transmission
HIV
Human immunodeficiency virus
Immunogenicity
Infections
Infectious diseases
Medical research
Neonates
Regression analysis
Tuberculosis
Vaccine efficacy
Vaccines
South Africa
Online AccessGet full text

Cover

More Information
Summary:In this phase 2 study, investigators evaluated the potential of two vaccines (H4:IC31 and BCG) to prevent the acquisition of tuberculosis infection and the subsequent development of sustained disease.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1714021